A phase II study of CI-980 in previously untreated extensive small cell lung cancer: an Ohio State University phase II research consortium study

Cancer Investigation
Jason P ThomasOhio State University Phase II Research Consortium Study

Abstract

CI-980, (ethyl (S)-(5-amino-1,2-dihydro-2-methyl-3-phenylpyrido[3,4-b] pyrazine-7-yl) carbamate 2-hydroxyethansulfonate (1:1)), is a water-soluble mitotic inhibitor. It acts by binding to the colchicine-binding site on tubulin, a site different from that of the vinca alkaloids, inhibiting tubulin polymerization. Cells exposed to CI-980 accumulate in M phase and die. In preclinical tumor models, CI-980 showed a broad spectrum of activity, including in multi-drug resistant tumor cell lines, with activity at least equal to that of vincristine. Extensive small cell lung cancer, despite its responsiveness to chemotherapy, is usually an incurable disease with survival in patients of less than one year. Due to the preclinical activity of CI-980 and its similar mechanism of action to drugs effective in small cell lung cancer, a phase II trial in extensive small cell lung cancer was initiated by The Ohio State University Phase II Research Consortium. A "window of opportunity" design was chosen where a short six-week trial of the drug was given unless there was significant objective response. Twelve patients were entered in the study and underwent a total of 16 cycles of chemotherapy. The median age of the patients was 54 years old (rang...Continue Reading

References

Sep 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·N MurrayN Voss
Feb 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D W MilesS G Spiro
Nov 1, 1985·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W K EvansG Deboer
Dec 1, 1982·American Journal of Clinical Oncology·M M OkenP P Carbone
Feb 5, 1998·CA: a Cancer Journal for Clinicians·S H LandisP A Wingo
Apr 29, 1998·Current Opinion in Oncology·M SorensenH H Hansen
Apr 27, 1999·Cancer Nursing·M Barton-Burke

❮ Previous
Next ❯

Citations

Jun 27, 2007·British Journal of Haematology·Kenneth C AndersonAnn T Farrell
Oct 21, 2015·Analytical Cellular Pathology (Amsterdam)·Daniele FanaleViviana Bazan
Nov 28, 2013·The Cochrane Database of Systematic Reviews·Marta Pelayo AlvarezXavier Bonfill Cosp
Jul 21, 2012·Pharmaceutical Research·Yan LuDuane D Miller

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.